Joint Mission of the United Nations Interagency Task Force on the Prevention and Control of Noncommunicable Diseases, Thailand 28-30 August 2018
A Joint Programming Mission of the United Nations Interagency Task Force (UNIATF) on the Prevention and Control of Non-Communicable Diseases (NCDs) to Thailand was conducted between 28-30 August 2018 at the invitation of the Government of Thailand. The Joint Mission consisted of representatives from 10 UN agencies and 4 Thai experts. The Mission met with a number of ministries and government agencies as well as civil society organizations, selected private sector entities and academic institutions.
Joint external evaluation of IHR core capacities of the Kingdom of Thailand: mission report: June 26-30, 2017
Thailand has implemented the IHR since they were first introduced in 1969 and has been actively involved in improving the Regulation since the 1980s. Volunteering to host a joint external evaluation (JEE) mission represents a continuation of the country’s engagement in, and leadership of, the IHR and is to be commended. This shows tremendous foresight and demonstrates the Government’s commitment to providing world-class health care to each of its citizens.
Building on the recent East Asia Summit Declaration for a malaria free Asia Pacific by 2030, and given the role of Thailand in these multi-country efforts, an in-depth review of the Thai Malaria Programme was considered timely and appropriate to reorient the current control interventions in line with the Greater Mekong Subregion (GMS) malaria elimination (2016-2030) initiative support by WHO and partners.
Field visits, intensive internal discussion and meeting were undertaken. Finding and actions points expressed by the reviewers would be useful to be considered by the programme and partners to achieve malaria elimination goals.
The WHO Global Malaria Programme issues regular reports about the status of artemisinin resistance in affected countries. The reports bring together the latest findings and conclusions about the state of resistance to artemisinins and artemisinin-based combination therapy (ACT), summarize WHO’s current policy and treatment recommendations, and highlight areas of concern.